Competitive binding studies and antigen capture assays were done with monoclonal antibodies (MAbs) raised against hog cholera virus (HCV) to map the corresponding epitopes. A model was constructed in which the 13 epitopes were situated in four distinct antigenic domains: A, B, C and D. Domain A was subdivided into A1, A2 and A3. The functional relevance of this model was assessed by the characterization of pestivirus strains, by neutralization studies with the MAbs, and by isolation of variants that escaped neutralization. The topographical arrangement of the epitopes, as constructed in the model, was corroborated by the functional assays. The MAbs that defined domains A1 and A2 recognized all 94 HCV strains tested. Domains A3, B, C and D varied among the HCV strains. Neutralization was observed with MAbs defining domains A1, B and C. Synergistic neutralization occurred using MAbs against domains A1 and B, and A1 and C, but not within the domains. With MAbs defining A1, B or C, variants could be isolated that escaped neutralization and immunostaining by these MAbs.
INTRODUCTION
Hog cholera virus (HCV) (synonym: swine fever virus), bovine viral diarrhoea virus (BVDV) and border disease virus (BDV) compose the genus pestivirus in the family Togaviridae (Westaway et al., 1985) . The viruses are closely related structurally and antigenically; infection with one virus induces, to varying extents, antibodies against the other viruses in this genus (Darbyshire, 1960; Dinter, 1963; Mengeling, 1963; Osburn, 1973; Wensvoortetal., 1989a) . The three viruses cannot be differentiated when infected monoiayers are immunostained with polyclonal antisera raised against any of the three, and must be differentiated using crossneutralization tests. The viruses have similar hydrodynamic properties, showing a buoyant density in sucrose of 1.12 g/cm 3 and a sedimentation coefficient of 138 + 11.5 (Laurie, 1979) . Among several proteins reported, three structural proteins (El, 55K to 57K; E2, 44K to 46K; C, 34K to 36K) have consistently been found (Enzmann & Weiland, 1978; Matthaeus, 1979) . Nothing is known about functional sites on these proteins, or about the location of supposedly shared antigenic structures.
Hog cholera is a disease of pigs, bovine viral diarrhoea of cattle, border disease of sheep; however, cross-infections by these viruses do occur (for review, see Van Oirschot, 1983) . A similar feature in the pathogenesis of the three viruses is their ability to induce congenital infections (Van Oirschot, 1983) . Hog cholera is an economically important and notifiable disease in most pig-producing countries; outbreaks are generally controlled by eradication programmes. HCV is routinely diagnosed in the laboratory using immunofluorescence tests (Ressang & Den Boer, 1968) . However, BVDV infections in pigs are also detected with conjugates of polyclonal immunoglobulins against HCV and can be mistaken for HCV infections (Terpstra & Wensvoort, 1988) . To facilitate differential diagnosis of pestivirus infections in pigs, we produced monoclonal antibodies (MAbs) against HCV strain Brescia and characterized a number of other pestivirus strains by immunostaining (Wensvoort et al., 1989 b) . This report presents the results of topographical and functional studies that were performed with these MAbs.
METHODS
Virus, cells and anti-HCV serum. HCV strain Brescia was biologically cloned by three times repeated endpoint dilution and grown in PK-15 cells in roller bottle cultures. As growth medium, Earle's MEM supplemented with antibiotics and 5~o foetal bovine serum (FBS) was used. The cells and FBS were free of pestivirus infection. The FBS was also free of antibodies against HCV and BVDV. Swine anti-HCV hyperimmune serum was produced in specific pathogen-free pigs (Terpstra et al., 1984) . Immunoglobulins were purified by ammonium sulphate precipitation and conjugated to horseradish peroxidase (HRPO), according to the method of Wilson & Nakane (1978) . The anti-HCV conjugate recognized HCV, BVDV and BDV when used to immunostain infected cell cultures and tissue sections.
MAbs. Thirteen lines of MAb-producing hybridomas ) were produced against gradient-purified HCV strain Brescia . The cells were multiplied in BALB/e mice. MAbs (numbered 1 to 13, respectively) were purified from ascitic fluid by ammonium sulphate precipitation. A complete set of anti-mouse immunoglobulin sera (Nordic) was used to determine the isotype of the MAbs in double immunodiffusion tests. MAb-HRPO conjugates were produced as described above. MAbs and the conjugates were stored in 50~ (v/v) glycerol at -20 °C at a protein concentration of 4 mg/ml. Competitive binding assay (CBA) . ELISA plates (Dynatech, M129A) were coated overnight at 4 °C with HCV antigen, partially purified from HCV Brescia-infected PK-15 cells by centrifuging frozen and thawed cell lysates through a 25 ~ (w/v) sucrose cushion, as described before . Plates were washed with 0.05 Tween 80 in demineralized water. MAb-HRPO conjugates were diluted in phosphate-buffered saline (PBS) containing 0.05~ Tween 80 (PBS-Tw) to a working dilution that resulted in 50~ to 70~ of the maximum absorbance. Each of the unconjugated MAbs was diluted 50-fold in the working dilution of the MAb-HRPO under study, after which the mixtures were transferred to the wells of ELISA plates. Each mixture and the conjugates alone were tested in quadruplicate. After incubation for 1 h at 37 °C, the plates were washed as described above, and 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) (Serva) and hydrogen peroxide were added. The Aa05 was measured after 4 h with a Titertek Multiskan spectrophotometer. Combinations of MAbs and MAb-HRPO conjugates that showed more than 50~ reduction of the A4os of the conjugate alone were retested with 10 -2, 10 -3 and 10 -4 dilutions of the unconjugated MAb.
Antigen capture assay (ACA). Roller bottle (1750 cm 2) cultures of PK-15 cells were infected with HCV Brescia and incubated for 48 h. The supernatant was discarded and infected cells were harvested by shaking with glass beads. Cells were suspended in PBS, then frozen and thawed. Cell lysates were sonicated twice for 10 s, after which Nonidet P-40 (NP40) was added to a final concentration of 1~ (v/v). Cell lysates were left for 1 h at room temperature, then clarified for 15 min at 1000 g. The supernatant was divided up and stored at -70 °C for use as HCV antigen in the ACA.
ELISA plates (Costar EIA 3590) were coated for 1 h at 37 °C with 100 gl of a 10 -3 dilution of the respective MAb in 50 mM-NaHCO3 (pH 9.6) per well. Plates were then washed as described above. MAb-HRPO conjugates were diluted in PBS-Tw and 10~ horse serum to the same dilution as used in the competitive binding studies. Fifty ~1 of conjugate was added to the wells of the coated ELISA plates. HCV antigen was diluted 1:10 in PBS-Tw and 50 Ixl was added to each well. Each conjugate was tested in quadruplicate with each MAb as coating antibody. A negative control was added to each plate, eight wells received 50 ~tl of the corresponding MAb-HRPO conjugate and 50 ktl PBS-Tw. The plates were incubated for 1 h at 37 °C, washed as described above, and then ABTS and H20~ were added. Absorbance was read after 17 h at 4 °C. An A from 0 to 0.199 was recorded as 0, from 0.2 to 0.399 as 1, etc.
Characterization ofpestiviruses. Ninety-four HCV strains, i.e. 30 laboratory strains that originated from several European and American laboratories, 57 Dutch field isolates, seven vaccine strains, and 27 BVDV strains and four BDV strains were characterized with the anti-HCV-HRPO and the MAb--HRPO conjugates. The viruses were grown in PK-15 cells or foetal bovine epithelial cells (a cell line established at this Institute). Infected monolayers were immunostained with various conjugates in an immunoperoxidase monolayer assay (IPMA; . This paper reports only the number of strains or isolates that were recognized by the various conjugates; detailed results will be published elsewhere (Wensvoort et al., 1989b) .
Neutralization by MAbs. Neutralizing titres against HCV Brescia were determined in duplicate in a neutralizing peroxidase-linked assay (NPLA; Terpstra et al., 1984) . Titres were expressed as the reciprocal of the dilution that prevented multiplication of 100 TCIDs0 of HCV Brescia. Neutralization indices were determined by incubating 10-fold dilutions of HCV Brescia in quadruplicate for 1 h at 37 °C in the absence or presence of MAb diluted 1 : 50. PK-15 cells were then added and the cultures were grown for 4 days at 37 °C in 5 ~ CO2. Indices were expressed as the log10 reduction of the virus titre by the MAb. Complement-mediated neutralization was studied by determining neutralization indices for the MAbs in the presence of rabbit complement. After the primary incubation of the virus-MAb mixtures, lyophilized rabbit serum (Sera-lab) was reconstituted and added to a final concentration of 0H, 5~ or 10~. The virus-MAb-complement mixtures were incubated for 30 min at 37 °C before PK-15 cells were added. HCV-positive and -negative pig serum and growth medium were tested as controls. Neutralization experiments were all performed in PK-15 cells grown in microtitre plates, and infected monolayers were immunostained with the anti-HCV-HRPO conjugate.
Synergism of MAbs. Synergism of neutralization was detected by titrating MAbs and mixtures of two MAbs, in the NPLA with approximately 44, 440 and 4400 TCIDso of HCV Brescia. Each MAb was tested in quadruplicate, alone and in combination with each of the other MAbs. Titres were expressed as described above, plotted on logarithmic paper against the virus dose, and then interpolated for 100 and 1000 TCIDs0. Synergism of a combination was expressed as the factor by which the actual titre was increased as compared with the expected arithmetic mean titre for that combination. Only when a combination had a titre at least four times higher than expected against both 100 and 1000 TCID5o was synergism considered to have occurred.
Detection of escape variants. To select virus variants that escaped neutralization by MAbs, we mixed 10-fold dilutions of HCV Brescia in growth medium with neutralizing MAbs 1 to 8 (final dilution 1 : 50) and incubated the mixture for 1 h at 37 °C. Virus-MAb mixtures were added to PK-15 cell suspensions that were then grown in microtitre plates for 4 days. The supernatants of the cell cultures were collected and stored at -70 °C. The monolayers were immunostained with the MAb-HRPO conjugate homologous to the selecting MAb, after which the number and appearance of infected monolayers were recorded. The monolayers were immunostained for a second time, this time with the polyclonal anti-HCV-HRPO conjugate. Virus variants that were not recognized by the MAb-HRPO conjugate were found in cultures that stained only on the second occasion, or in cultures in which many more cells were stained after the second time. From the corresponding supernatants, virus was isolated in PK-15 cells. After two cell culture passages without MAb, the escape variants were characterized in the IPMA. To assess homogeneity, we titrated the isolate in 10-fold dilutions and grew it in PK-15 cells. After 4 days, the virus titration was immunostained with all 13 MAbs and the polyclonal anti-HCV conjugate. A virus titre of each isolate was thus determined for each MAb. Only isolates that had a titre at least 10000-fold lower when stained with the selecting MAb than when stained with other MAbs or with the anti-HCV conjugate, were considered to contain a variant that lacked the epitope specific for the selecting MAb. These variants were used to determine neutralization indices for MAbs 1 to 8, as described above.
RESULTS

Topographical analysis Competitive binding assay
Each MAb, diluted 1:50, was allowed to compete for its epitope on HCV Brescia with all 13 MAb-HRPO conjugates, thus 169 combinations were tested and percentages of inhibition of the conjugate by the MAb were calculated. This resulted in two groups of MAb/MAb-HRPO combinations. In one group of 97 combinations, no competition was observed. The mean inhibition of this group was 0 ~ and the standard deviation was 13.2 ~. In the second group of 72 combinations, competition was observed. The mean inhibition of this group was 87~ and the standard deviation was 8.2~o. The highest inhibition in the first group was 38~. In the second group, the lowest inhibition was 62~.
On the basis of these findings, the MAb/MAb-HRPO combinations were divided into those with < 50~ and those with > 50~o competition (Fig. 1) . All MAb/MAb-HRPO combinations from the second group were retested with higher dilutions of the unconjugated MAb. All combinations of MAb and conjugate that effected more than 50 ~ reduction of the signal of the conjugate alone in the 1:50 dilution of the MAb also did so in the 1:100 dilution of the MAb. All unconjugated MAbs reduced the signal of their conjugated homologue by more than 50 ~ at the 1 : 1000 dilution. In most cases, reciprocal competition, in which one MAb competed with the conjugate of another MAb and vice versa, was detected. Non-reciprocal competition was effected by MAbs l, 8, 3 and 7 on the conjugated MAb 12, by MAb 5 on the conjugated MAbs 6, 2, 3, 7, 10, 11, 9 and 12, by MAb 2 on the conjugated MAbs 7, 10, 11, 9 and 12, and by MAb 4 on the conjugated MAbs 10 and 11. Enhanced binding of conjugates by MAbs, as found by Heinz et al. (1984) in CBA performed with MAbs directed against tick-borne encephalitis virus, was not seen.
The relations between the competing MAbs, diluted 1 : 50 and 1 : 100, and the conjugates were used to group the epitopes in four antigenic domains: A, B, C and D (Fig. 2a) . The relations between the competing MAbs, diluted 1 : 1000, and the conjugates permitted the subdivision of domain A (Fig. 2b) . Within the domains, the MAbs defining the epitopes differed slightly. In domain A, only MAbs, 9, 10 and 11 had identical relations with each other and with all the other MAbs, and thus reacted identically with the HCV antigen under these conditions. At the same time, MAbs 2, 3, 4, 7 and 12 reacted differently in the competition assays with all other MAbs, thus demonstrating that each has a unique relationship with HCV. In domain C, MAbs 1 and 8 competed with each other and competed reciprocally with MAb 5 and non-reciprocally with MAb 12, while MAb 5 also competed non-reciprocally with seven other MAbs. MAb 5 was thus unique, whereas MAbs 1 and 8 reacted identically with the HCV antigen under these conditions.
Antigen capture assay
Each MAb was tested as coating antibody with each M A b -H R P O conjugate, and each combination was judged for its capacity to recognize HCV antigen in infected cell lysate treated with NP40. A positive signal in A C A meant that both MAbs could bind simultaneously indicating that the epitopes were located separately from each other. A negative signal meant either that the two MAbs could not bind simultaneously and thus recognized an overlapping or adjacent epitope or that the respective epitopes were not located on the same protein (Fig. 3) . When a MAb was used as coating antibody and its homologous M A b -H R P O was used as conjugate, no HCV antigen was recognized. This demonstrated that aggregate formation by proteins, in which the same epitope would appear twice on the aggregate, was not a problem in ACA. Combinations of MAbs were only able to recognize the antigen when the two MAbs were 
Functional analyses Characterization of pestiviruses
Immunostaining (IPMA) of cell cultures that were infected with 125 different pestivirus strains or isolates revealed that MAbs 2, 3, 4 and 7 (subdomain A1), and 9, 10 and 11 (subdomain A2) consistently recognized all 94 HCV strains or isolates tested (Table 1) . MAbs 6 (domain B), 1, 5 and 8 (domain C), 12 (subdomain A3) and 13 (domain D) did not label several HCV strains or isolates; thus the epitopes defined by these MAbs were absent from these viruses. None of the latter MAbs detected the same variation; however, MAbs 1 and 8 were very similar, MAb 8 stained the same viruses as MAb 1, and one strain more. None of the 27 BVDV or the four BDV strains or isolates was detected by the 13 MAbs, whereas the polyclonal anti-HCV conjugate recognized all 125 pestiviruses. No reaction was observed with uninfected monolayers, thus all MAbs were specific for HCV as grown in cell culture. The MAbs detected a high level of epitopic variability among HCV. This finding confirms the findings of an earlier study , in which five different variants were isolated from the blood of a pig infected with one virulent HCV strain.
Neutralization by MAbs
MAbs 1 to 8 (domains A1, B and C) neutralized strain Brescia to varying extents (Table 1) . Two MAbs (2 and 6) had low titres and indices, two (3 and 4) had moderately high titres and indices, and four (l, 5, 7 and 8) had high neutralizing titres and indices. MAbs 9 to 13 did not neutralize strain Brescia. Neutralization indices were not enhanced by the addition of complement.
Synergism of MAbs
To study the synergistic effect of MAbs in neutralization tests, titres of individual MAbs and combinations of MAbs were determined against HCV Brescia. Synergism was observed only with MAbs 1 to 8, and only specific pairs interacted synergistically. One member of each pair was always MAb 2, 3, 4 or 7 (domain A1), and the other member was always MAb 1, 5, 8 (domain C) or 6 (domain B) ( Table 2) .
Detection of escape variants
Viral variants were isolated that escaped neutralization and were not immunostained by specific MAbs. With the eight neutralizing MAbs used for selection, 11 non-neutralizable variants were isolated, seven of which were different when immunostained with the full set of MAbs in IPMA (Table 3 ). The neutralization indices of MAbs 1 to 8 were determined for these eight (Table 3 ). Viral variants that were isolated with MAbs directed against domain A, B or C were no longer neutralized or detected in immunostaining by MAbs directed against A, B or C, respectively, but had normal reactivity patterns with other MAbs. Results obtained with MAbs 1, 5 and 8 directed against domain C permitted a division of this domain. MAb 5 was used to isolate a variant that was neutralized by MAbs 1 and 8 but not by MAb 5; MAbs 1 and 8 were used to isolate variants that were neutralized by MAb 5, but not by MAbs 1 and 8. In general, we found that MAbs 1 to 8 neutralized the viral variants that they recognized in the IPMA. Three variants, however, were recognized by a MAb in immunostaining, but were not neutralized by this MAb; these were variant C-lc5 and MAb 8, variant A-4d7 and MAbs 3 and 7, and variant A-4d12 and MAb 7. Note that escape variants could be found in vitro that were no longer recognized by MAbs directed against domains A1 and A2. This finding apparently contradicts 
Isotype, detection of stra& variation by, and neutralization with 13 MAbs against HCV Brescia
MAb A , Results at 100 TCIDs0/1000 TCID50, thus the mixture of equal volumes of MAb 2 and MAb 6 gave an 18-fold increase with 100 TCIDso and a 28-fold increase with 1000 TCIDs0, as compared with the mean titre of both MAbs titrated separately. Combinations of MAbs that are considered synergistic. MAbs 9 to 13 did not neutralize or cause synergism.
Synergism of MAbs in neutralization test*
C~ t~ oo to oo -.d to Table 3 . the finding that these domains are conserved among 94 laboratory strains and field isolates of HCV. However, it could also indicate that although the variants are suited to a tissue culture flask environment, their particular genotype does not permit them to predominate in vivo. One of the viral variants (A-7a5) that was not recognized by MAbs directed against domains A1 and A2 was cloned by endpoint dilution three times and was subsequently grown for seven passages in cell culture. During these passages, the variant was not recognized in immunostaining with the MAbs that defined A1 and A2.
Detection of escape variants
DISCUSSION
Thirteen MAbs, produced against HCV strain Brescia, were used to analyse epitopes topographically and functionally. CBA and antigen capture assays ACA were used for topographical analyses.
Competition between a MAb and a MAb conjugate in CBA indicates that the epitopes that are recognized by the two MAbs overlap or are adjacent on the antigen (Stone & Nowinsky, 1980) , especially for reciprocally competing MAbs. Non-reciprocal competition may be explained in several ways. The affinity of the two MAbs may differ greatly; the binding of one MAb may induce a change in conformation that alters the binding site of the other MAb; the binding of one MAb may sterically hinder the binding of the other MAb; conjugating one MAb to peroxidase may alter the ability of the MAb to bind. Since the information gained from nonreciprocal competition was not straightforward, only the results that indicated homologous and reciprocal competition were incorporated in Fig. 2 . Four distinct antigenic domains, A, B, C and D, were defined (Fig. 2a) . Domain A was divided into two when the more discriminative 1 : 1000 dilution of the competing MAbs was used (Fig. 2b) . The domains consist of adjacent or overlapping epitopes.
The ability of pairs of MAbs and MAb--HRPO conjugates to recognize HCV antigen was determined in ACA. The HCV antigen was obtained by treating HCV-infected cell lysates with the non-ionic detergent NP40. Because homologous pairs of MAbs and MAb conjugates scored negative in the ACA, we reasoned that under the test conditions epitopes were available only once on each protein. The same four domains were defined in ACA as in CBA, but domain A was divided into subdomains Al, A2 and A3 ( Fig. 2 and 4) . Fig. 4 can therefore serve as an abstract model depicting the spatial relations between the 13 epitopes.
The biological relevance of this model was assessed by immunostaining pestivirus strains, by neutralization studies, and by isolating variants that escaped neutralization by various MAbs. The topographical arrangement of the domains was fully corroborated by the functional assays (Fig. 4) . The domains were HCV-specific. MAbs used to define subdomains A1 and A2 consistently reacted with all 94 HCV strains or isolates tested. The domains B, C, D and A3 varied among 30 laboratory strains, 57 field isolates and seven vaccine strains of HCV (Table 1) . Because of their specificity for HCV, MAbs can now be used routinely to differentiate between HCV and BVDV infections in pigs (Terpstra & Wensvoort, 1988) . The widely used Chinese vaccine virus strain (C strain) is always recognized by the MAbs directed against A1, A2 and D, but lacks the epitopes for the MAbs directed against A3, B and C. The 57 Dutch field strains are always recognized by the MAbs directed against AI and A2 and by MAbs 1 and 8. Because of this feature, these MAbs can be used to differentiate between infections caused by field strains or by the vaccine virus, strain C (Wensvoort et al., 1989b) .
The eight MAbs directed against domains A1, B and C neutralized HCV (Table 1) . Thus, domain A1 is conserved among HCV strains and is involved in neutralization.
Combining MAbs directed against domain A1 with MAbs directed against either B or C produced strong synergistic effects in neutralization tests. These were not seen with combinations of MAbs directed against the same domain (Table 2) . Synergism was more pronounced with high virus doses, when antigen was in relative excess. In CBA, there were no MAbs that enhanced the binding of other MAbs; therefore, it is unlikely that the synergism can be explained by enhanced binding of two MAbs to the virion. Synergism occurred only when MAbs that individually neutralized were combined. This finding is at variance with that of A negative score in ACA indicated that the epitopes were adjacent or spatially overlapping, these epitopes are grouped at each comer. The epitopes were grouped in four antigenic domains: A, B, C and D. Domain A was divided into subdomains A 1, A2 and A3. By testing the MAbs in neutralization tests it was shown that domains AI, B and C are involved in neutralization. MAbs directed against domains A1 and A2 bound to all viral strains and isolates tested. Symbols: ~, neutralizing site; k~, conserved site; *--~, synergism. Peiris et al. (1982) , who reported that a combination of two non-neutralizing MAbs was able to neutralize the West Nile flavivirus.
The observed synergistic effect is not simply the result of multiple binding to more 'critical sites' on the virion, as proposed by DeUa-Porta & Westaway (1978) . Neither can it be solely explained by assuming that more and more complex virion-antibody aggregates are formed by which infection is prevented. Neither of these explanations accounts for the fact that synergism does not occur when MAbs that define domains B and C are combined. It appears that antibody must attach to domain A1. Hence antibodies against domain A1 may play a specific role in neutralizing the virus, as a function of domain A1 or of the antibodies directed against A1. All MAbs defining A1 belong to the IgG2 isotype, and all MAbs defining domains B and C belong to the IgG 1 isotype (Table 1) . Klaus et al. (1979) found that mouse IgG2 antibodies are involved in complement activation, whereas IgG 1 antibodies are not. However, addition of complement did not enhance neutralization; complement-mediated neutralization can thus not be a cause of the observed synergism.
Neutralizing MAbs 1 to 8 were used to select seven different variants that escaped neutralization and recognition in the IPMA. MAbs that were directed against a certain domain selected viral variants that escaped neutralization by MAbs directed against that domain. These viral variants, however, were always neutralized and immunostained by MAbs defining the other domains (Table 3 ). This finding further illustrates the independence of the domains. Three escape variants (C-lc5, A-4d7 and A-4d12) showed the phenomenon of unimpaired immunostaining but reduced neutralization by a MAb. In every case, these MAbs belonged to the same group as the MAb that was used to select the variant. How these variants bind to the MAb but are no longer neutralized by it is not understood. This phenomenon has also been observed in studies with poliovirus, in which an escape mutant was recognized by immunoprecipitation but was no longer neutralized by a selecting MAb (Thomas et al., 1986) .
By using MAbs against domain
In conclusion, CBA and ACA were used to define an abstract model of an antigenic region of HCV, in which 13 epitopes form four antigenic domains: A, B, C and D. Domain A was divided into subdomains A1, A2 and A3. Functional analyses supported virtually all these results (Fig.  4) . In a future report (G. Wensvoort & J. Boonstra, unpublished data) we will demonstrate that these domains are all located on the major envelope protein of HCV.
